Stakeholders warn of potential burdens in FDA’s drug delivery guidance
Regulatory NewsEmily Hayes
Combination productsCombination products/companion diagnosticsGuidanceMedical DevicesProduct LifecycleUnited StatesUS Food and Drug Administration (FDA)